Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Creo Medical Seeks To Make Flexible Electrosurg Tech Attainable For The 'Regular' Endoscopist

Executive Summary

Surgical endoscopy specialist Creo Medical is picking up the pace with its surgeon training program to increase awareness of its CROMA advanced electrosurgical platform within the clinical community. The training – aimed at the majority of "regular endoscopists" – is an integral part of Creo's commercial roll-out plan for the first device to emerge from the platform, which is targeting the gastroenterology field.

You may also be interested in...



Creo Gets Early FDA Green Light For Endoscopy Device

Surgical endoscopy specialist Creo Medical has received the nod of approval to start selling its Speedboat RS2 device and CROMA platform in the US. The FDA cleared the use of the surgical endoscopy device ahead of schedule, processing the company's 510(k) application just 49 days from submission.

Creo Medical Braves Public Market To Score $25m IPO

Surgical endoscopy specialist Creo Medical Group plc has met its IPO target and raised £20m ($25m) ahead of its listing on the London Stock Exchange's Alternative Investment Market (AIM) on Friday 9 December.

Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio

Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT105151

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel